Cargando…

Lipid-Lowering Responses to Dyslipidemia Determine the Efficacy on Liver Enzymes in Metabolic Dysfunction-Associated Fatty Liver Disease with Hepatic Injuries: A Prospective Cohort Study

PURPOSE: Effective treatment of dyslipidemia with lipid-lowering agents is pivotal in the management of metabolic-associated fatty liver disease (MAFLD) for preventing cardiovascular complications. We explored the associations between improvements in liver injuries indicated by changes in transamina...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liao, Xianhua, Ma, Qianqian, Wu, Tingfeng, Shao, Congxiang, Lin, Yansong, Sun, Yanhong, Feng, Shiting, Wang, Wei, Ye, Junzhao, Zhong, Bihui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9030404/ https://www.ncbi.nlm.nih.gov/pubmed/35464261 http://dx.doi.org/10.2147/DMSO.S356371

Ejemplares similares

Distinct Dose-Dependent Association of Free Fatty Acids with Diabetes Development in Nonalcoholic Fatty Liver Disease Patients
por: Li, Fuxi, et al.
Publicado: (2021)

Varied Relationship of Lipid and Lipoprotein Profiles to Liver Fat Content in Phenotypes of Metabolic Associated Fatty Liver Disease
por: Wu, Tingfeng, et al.
Publicado: (2021)

Normalization of γ-glutamyl transferase levels is associated with better metabolic control in individuals with nonalcoholic fatty liver disease
por: Ma, Qianqian, et al.
Publicado: (2021)

The Ability of Lipoprotein (a) Level to Predict Early Carotid Atherosclerosis Is Impaired in Patients With Advanced Liver Fibrosis Related to Metabolic-Associated Fatty Liver Disease
por: Wu, Tingfeng, et al.
Publicado: (2022)

Metabolic benefits of changing sedentary lifestyles in nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials
por: Ma, Qianqian, et al.
Publicado: (2022)

Effect of orlistat on liver fat content in patients with nonalcoholic fatty liver disease with obesity: assessment using magnetic resonance imaging-derived proton density fat fraction
por: Ye, Junzhao, et al.
Publicado: (2019)

Vitamin D Status Presents Different Relationships with Severity in Metabolic-Associated Fatty Liver Disease Patients with or without Hepatitis B Infection
por: Luo, Ling, et al.
Publicado: (2022)

Insulin resistance exhibits varied metabolic abnormalities in nonalcoholic fatty liver disease, chronic hepatitis B and the combination of the two: a cross-sectional study
por: Ye, Junzhao, et al.
Publicado: (2019)

Metabolomics to identify fingerprints of carotid atherosclerosis in nonobese metabolic dysfunction-associated fatty liver disease
por: Shao, Congxiang, et al.
Publicado: (2023)

Discrepancies between Nonalcoholic and Metabolic-associated Fatty Liver Disease by Multiple Steatosis Assessment
por: Shao, Congxiang, et al.
Publicado: (2022)

Distinct Cause of Death Profiles of Hospitalized Non-alcoholic Fatty Liver Disease: A 10 Years' Cross-Sectional Multicenter Study in China
por: Lin, Yansong, et al.
Publicado: (2021)

Compositional alterations of gut microbiota in nonalcoholic fatty liver disease patients: a systematic review and Meta-analysis
por: Li, Fuxi, et al.
Publicado: (2021)

Steatosis grading consistency between controlled attenuation parameter and MRI-PDFF in monitoring metabolic associated fatty liver disease
por: Shao, Cong xiang, et al.
Publicado: (2021)

Impact of skeletal muscle mass evaluating methods on severity of metabolic associated fatty liver disease in non-elderly adults
por: Zhou, Ting, et al.
Publicado: (2023)

The Additive Values of the Classification of Higher Serum Uric Acid Levels as a Diagnostic Criteria for Metabolic-Associated Fatty Liver Disease
por: He, Jie, et al.
Publicado: (2022)

Age patterns of nonalcoholic fatty liver disease incidence: heterogeneous associations with metabolic changes
por: Lin, Yansong, et al.
Publicado: (2022)

Dynamic monitoring with shear wave elastography predicts outcomes of chronic hepatitis B patients with decompensated cirrhosis
por: Ye, Junzhao, et al.
Publicado: (2021)

Prevalence and Significance of Antinuclear Antibodies in Biopsy-Proven Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
por: Luo, Ling, et al.
Publicado: (2022)

Alterations in Circulating Bile Acids in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis
por: Lai, Jiaming, et al.
Publicado: (2023)

Dyslipidemia and Fatty Liver Disease in Overweight and Obese Children
por: Deeb, Asma, et al.
Publicado: (2018)

Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease
por: Martin, Anna, et al.
Publicado: (2022)

Lipid-Lowering Nutraceuticals for an Integrative Approach to Dyslipidemia
por: Cheung, Brian, et al.
Publicado: (2023)

Is there a role of lipid-lowering therapies in the management of fatty liver disease?
por: Tzanaki, Ismini, et al.
Publicado: (2022)

Pathogenesis of Insulin Resistance and Atherogenic Dyslipidemia in Nonalcoholic Fatty Liver Disease
por: Akhtar, Daud H., et al.
Publicado: (2019)

The Associations between Liver Enzymes and Cardiovascular Risk Factors in Adults with Mild Dyslipidemia
por: Park, Eun-Ock, et al.
Publicado: (2020)

Comparison of the relationships of alcoholic and nonalcoholic fatty liver with hypertension, diabetes mellitus, and dyslipidemia
por: Toshikuni, Nobuyuki, et al.
Publicado: (2013)

Nonalcoholic Fatty Liver Disease: Dyslipidemia, Risk for Cardiovascular Complications, and Treatment Strategy
por: Zhang, Qing-Qing, et al.
Publicado: (2015)

Mitochondrial metabolic dysfunction and non-alcoholic fatty liver disease: new insights from pathogenic mechanisms to clinically targeted therapy
por: Zheng, Youwei, et al.
Publicado: (2023)

Association of Drug-Metabolizing Enzyme and Transporter Gene Polymorphisms and Lipid-Lowering Response to Statins in Thai Patients with Dyslipidemia
por: Vanwong, Natchaya, et al.
Publicado: (2022)

Differing Associations between Fatty Liver and Dyslipidemia According to the Degree of Hepatic Steatosis in Korea
por: Han, Ji Min, et al.
Publicado: (2019)

New perspective on type 2 diabetes, dyslipidemia and non‐alcoholic fatty liver disease
por: Matsuzaka, Takashi, et al.
Publicado: (2020)

Increased detection rates of advanced colorectal adenoma in women with metabolic dysfunction-associated fatty liver disease
por: Gong, Yan, et al.
Publicado: (2023)

Postprandial dysfunction in fatty liver disease
por: Grandt, Josephine, et al.
Publicado: (2023)

The latest evidence on the impact of fatty liver on liver-related outcomes and mortality in chronic hepatitis B
por: Mao, Xianhua, et al.
Publicado: (2023)

Non-alcoholic fatty liver disease: relation to juvenile obesity, lipid profile, and hepatic enzymes
por: Altalebi, Raghid Reyadh, et al.
Publicado: (2023)

Polymorphisms of lipid metabolism enzyme-coding genes in patients with diabetic dyslipidemia
por: Vardarlı, Aslı Tetik, et al.
Publicado: (2017)

Constitutive Activation of AKT2 in Humans Leads to Hypoglycemia Without Fatty Liver or Metabolic Dyslipidemia
por: Minic, Marina, et al.
Publicado: (2017)

Associations of Fatty Liver Disease with Hypertension, Diabetes, and Dyslipidemia: Comparison between Alcoholic and Nonalcoholic Steatohepatitis
por: Toshikuni, Nobuyuki, et al.
Publicado: (2017)

Another Kid on the Block: Long-acting FGF21 Analogue to Treat Dyslipidemia and Fatty Liver
por: Yang, Ranyao, et al.
Publicado: (2021)

Hepatic Nampt Deficiency Aggravates Dyslipidemia and Fatty Liver in High Fat Diet Fed Mice
por: Wang, Dao-Xin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_clnodslmb58ls06ocg7vfa0q9r